VTE anticoagulation - DOAC selection & duration
VTE DOAC choice · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
After confirming venous thromboembolism, the key decisions are agent choice (usually a direct oral anticoagulant), appropriate dosing phases, and treatment duration determined by whether the event was provoked, unprovoked or cancer-associated.
Red flags
- Haemodynamic instability (massive PE - consider thrombolysis)
- Active major bleeding
- Severe renal impairment (CrCl <15-30) limiting DOAC use
- Triple-positive antiphospholipid syndrome (DOAC contraindicated)
- Recurrent VTE despite compliant anticoagulation
Assessment
Differential diagnosis
- Provoked VTE (surgery, immobility, oestrogen)
- Unprovoked VTE
- Cancer-associated thrombosis
- Antiphospholipid syndrome
- Recurrent VTE on anticoagulation
Investigations
- Confirm VTE (Doppler/CTPA) and assess clot burden
- FBC, renal and liver function (dose/agent selection)
- Weight and bleeding risk assessment
- Pregnancy test in women of childbearing age
- Consider cancer assessment in unprovoked VTE (history, exam, age-appropriate screening)
- Antiphospholipid testing if clinically indicated (especially recurrent/arterial)
Management
- Confirm diagnosis and ensure the patient is haemodynamically stable (exclude high-risk PE needing thrombolysis)
- Assess renal function, bleeding risk, weight, drug interactions and patient preference
- Choose a DOAC first line for most non-cancer VTE (NICE preference: apixaban or rivaroxaban)
- Use the correct loading phase: higher-dose lead-in for apixaban and rivaroxaban, or 5 days LMWH before dabigatran/edoxaban
- Use LMWH in pregnancy, severe renal impairment, antiphospholipid syndrome (avoid DOACs, use warfarin), and extremes of weight where evidence is limited
- For cancer-associated VTE offer a DOAC (edoxaban/rivaroxaban/apixaban) or LMWH, weighing GI/urothelial bleeding risk
- Treat provoked VTE with a transient risk factor for 3 months
- Continue beyond 3 months (often long term) for unprovoked VTE, recurrent events, or active cancer, balancing bleeding risk
- Consider reduced-dose apixaban or rivaroxaban for extended prophylaxis after initial treatment
- Review periodically, reassess bleeding risk, and ensure adherence and monitoring of renal function
Drugs & doses
Apixaban 10 mg PO twice daily for 7 days then 5 mg twice daily (2.5 mg BD for extended phase)
Rivaroxaban 15 mg PO twice daily for 21 days then 20 mg once daily (10-20 mg OD extended)
Edoxaban 60 mg PO once daily after >=5 days LMWH (30 mg if CrCl 15-50 or low weight)
Dabigatran 150 mg PO twice daily after >=5 days LMWH; LMWH e.g. dalteparin/enoxaparin weight-based for cancer/pregnancy
Disposition
Ambulatory management for low-risk DVT/PE; admit high-risk PE; anticoagulation clinic / primary care follow-up with scheduled review.
Complications & pitfalls
- Major haemorrhage
- Recurrent VTE
- Post-thrombotic syndrome
- Chronic thromboembolic pulmonary hypertension
- DOAC failure in antiphospholipid syndrome
Exam pearls
- Apixaban and rivaroxaban need no LMWH lead-in; edoxaban and dabigatran do
- Avoid DOACs in triple-positive antiphospholipid syndrome - use warfarin
- Cancer-associated VTE: DOACs are effective but watch GI/urothelial bleeding
- Unprovoked VTE often warrants indefinite anticoagulation if bleeding risk is acceptable
- Reassess renal function and bleeding risk at every review
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.